secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057710
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B
--------------------------------------------------------------------------------

- Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).
- Tests processed 626,200 (+28% YoY); oncology tests 71,000 (+102% YoY).
- Net loss $136.9M ($1.23/share) vs $138.6M ($1.45) in prior year; loss per share improved.
- Raised 2023 revenue guidance to $995M-$1.015B from prior $990M-$1.0B; gross margin guidance unchanged at 41%-44%.
- Secured Medicare coverage for Prospera heart transplant test and first commercial coverage for Signatera (Blue Shield CA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/0001104659-23-057710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923057710/tm2314862d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer